



---

Facial Cleanser — Rinse-off · Sulfate-Free

**DOSSIER — FULL TECHNICAL PACKAGE**

Target Markets: EU · India

SAMPLE REPORT

April 2026

CONFIDENTIAL

[theformulator.ai](https://theformulator.ai)



## Table of Contents

1. Executive Summary
2. Formula — Variant A
3. Processing Notes
4. Safety Overview
5. Regulatory Detail
6. Market Intelligence
7. Formulation Notes
8. Preservation Rationale
9. Stability Risk Assessment
  - 9a. Standard Protocol
  - 9b. Supply Chain Advisory — Tropical Markets
10. Manufacturing Brief
11. Technical Ingredient Data
12. Claims Substantiation Protocols
13. Research Citations
14. Regulatory Appendix



## 1. Executive Summary

This dossier presents a sulfate-free brightening face wash formulated for EU and India markets. The formulation uses Disodium Laurylglucosides Hydroxypropyl Citrate as the primary surfactant — a next-generation APG citrate ester ranked highest in our mildness database of 1,170 surfactants. Active ingredients include Niacinamide (3%) for brightening and Centella Asiatica Extract (1%) for soothing. All ingredients pass regulatory screening for both target markets, with one advisory note regarding the novel surfactant's listing status in India. Overall confidence score: 88% (green band).

## 2. Formula — Variant A

INCI Name	Ph.	%	Function	Safety	Conf.	CAS
Aqua	A	q.s.	Solvent	—	—	7732-18-5
Glycerin	A	5.00	Humectant	● 0.0	HIGH	56-81-5
Niacinamide	A	3.00	Brightening active	● 0.2	HIGH	98-92-0
Disodium Laurylglucosides Hydroxypropyl Citrate	A	15.00	Primary surfactant	● 0.4	MED	2481100-10-9
Coco-Glucoside	A	5.00	Co-surfactant	● 0.8	MED	110615-47-9
Cocamidopropyl Betaine	A	4.00	Amphoteric co-surfactant	● 1.9	MED	61789-40-0
Xanthan Gum	B	0.30	Viscosity modifier	● 0.0	HIGH	11138-66-2
Centella Asiatica Extract	B	1.00	Soothing active	● 0.3	MED	84696-21-9
Phenoxyethanol (and) Ethylhexylglycerin	C	0.90	Preservative system	● 2.5	MED	122-99-6
Citric Acid	C	q.s.	pH adjuster	● 0.5	HIGH	77-92-9

## 3. Processing Notes

**Phase A — 45°C:** Combine water and glycerin in main vessel. Heat to 45°C. Dissolve niacinamide completely before adding surfactants. Add Disodium Laurylglucosides Hydroxypropyl Citrate first — stir gently until uniform. Follow with Coco-Glucoside and Cocamidopropyl Betaine. Avoid high-shear mixing to prevent excessive foam.

**Phase B — 40°C:** Pre-hydrate Xanthan Gum in a small portion of glycerin (1:3 ratio) for 10 minutes before dispersing into Phase A — this prevents fisheyes. Add Centella Asiatica Extract and stir until homogeneous.

**Phase C — below 40°C:** Cool batch to below 40°C. Add Phenoxyethanol (and) Ethylhexylglycerin. Adjust pH to 5.0–5.5 with citric acid solution (50%). Measure pH at 25°C.

**Final:** Mix gently for 5 minutes. Target viscosity 2,000–4,000 cP. Do not exceed 50°C at any stage.

## 4. Safety Overview

Per-ingredient safety scores. Medium and high confidence only. Scores derived from ECHA CLP, CIR, IARC, NTP, and PubMed sources.

INCI Name	Score	Conf.	Assessment Notes
Glycerin	● 0.0	HIGH	No hazard signals across all 6 axes. CIR: safe as used.
Niacinamide	● 0.2	HIGH	CIR: safe as used in leave-on and rinse-off. No sensitization below 5%. IARC: not classified.
Disodium Laurylglucosides Hydroxypropyl Citrate	● 0.4	MED	Novel APG citrate. No CLP classifications. No IARC/NTP listing. Limited long-term data. Source: PubMed literature extraction.
Coco-Glucoside	● 0.8	MED	CIR: safe in rinse-off up to 12%. Irritation axis: 0.8 (very low). No sensitization classification.



INCI Name	Score	Conf.	Assessment Notes
Cocamidopropyl Betaine	● 1.9	MED	Sensitization axis: 1.9. NACDG prevalence: 1.7%. Known sensitizer attributed largely to DMAPA impurity. ECHA H317 classification. Irritation: 0.5 (low).
Phenoxyethanol	● 2.5	MED	Sensitization: 5.0. Systemic toxicity: 3.0. Irritation: 1.5. SCCS: safe at max 1.0%. EU Annex V restricted.
Ethylhexylglycerin	● 0.8	MED	Low hazard. CIR: safe as used up to 1.0%. Mild skin conditioning properties.
Xanthan Gum	● 0.0	HIGH	No hazard signals. CIR: safe as used. GRAS for food — well-established safety profile.
Centella Asiatica Extract	● 0.3	MED	Very low hazard. Rare case reports of allergic contact dermatitis in literature — not CLP classified. CIR: safe in current practices.
Citric Acid	● 0.5	HIGH	Irritation potential at high concentrations only. GRAS. pH adjuster use levels pose no concern. ECHA: H319 (eye irritation) at neat concentrations.

**Phenoxyethanol detail:** Sensitization score of 5.0 warrants attention for sensitive-skin positioning. However, at 0.80% in a rinse-off product with <30 seconds skin contact, the exposure-adjusted risk is significantly lower than in a leave-on application. EU restricts to max 1.0% (Annex V/29) — this formulation is compliant.

## 5. Regulatory Detail

INCI Name	EU	India
Aqua	Permitted	Permitted
Glycerin	Permitted	Permitted
Niacinamide	Permitted	Permitted
Disodium Laurylglucosides Hydroxypropyl Citrate	Permitted (REACH)	Not listed (novel)
Coco-Glucoside	Permitted	Permitted
Cocamidopropyl Betaine	Permitted	Permitted
Xanthan Gum	Permitted	Permitted
Centella Asiatica Extract	Permitted	Permitted
Phenoxyethanol	Restricted — max 1.0% Annex V, Entry 29	Permitted — max 1.0%
Ethylhexylglycerin	Permitted	Permitted
Citric Acid	Permitted	Permitted

**Advisory:** Disodium Laurylglucosides Hydroxypropyl Citrate is REACH-registered (EU) and US cosmetic-listed but not in India's IS 4707 positive list. Regulatory notification under Cosmetics Rules 2020 may apply. Consult regulatory affairs before India market launch.

## 6. Market Intelligence

Ingredient Pair	Products	Insight
Niacinamide + Glycerin	18,421	Most common pairing in brightening face washes. 73% of niacinamide cleansers.
Niacinamide + Centella Asiatica	4,218	+42% YoY in India brightening launches 2024–2025.
Cocamidopropyl Betaine + Coco-Glucoside	3,847	Standard mild sulfate-free pairing. High consumer acceptance.
Niacinamide + Phenoxyethanol	12,093	Common active-preservative pairing. No compatibility issues.

**Concentration benchmarking:** Niacinamide median in APAC brightening cleansers: 2.5% (IQR 1.5–4.0%). This formulation at 3.0% is above median — defensible for efficacy claims.

## 7. Formulation Notes

**1. Surfactant system selection.** Disodium Laurylglucosides Hydroxypropyl Citrate selected as primary surfactant based on mildness ranking from Zein Number data — top percentile in our 1,170-surfactant database. 100% naturally



derived, no ethoxylation, no PEGs. COSMOS approved. Paired with Coco-Glucoside (APG, foam stability) and Cocamidopropyl Betaine (viscosity, foam quality).

**2. Niacinamide at 3%.** Clinical data supports significant brightness improvement at 4–8 weeks. 3% balances efficacy with formulation stability — higher concentrations can cause flushing and reduce clarity in surfactant systems.

**3. pH strategy.** pH 5.0–5.5: skin-compatible, within PE+EHG effective range (3.0–8.0), optimal viscosity from xanthan network. CAPB viscosity is also pH-sensitive.

**4. Centella at 1%.** Functional level for soothing claims. Below 0.5% is sub-efficacious in rinse-off given short contact time. High-growth pairing with Niacinamide in India market.

**5. No fragrance.** Omitted for sensitive-skin positioning. Fragrance is #1 cause of cosmetic contact dermatitis. If required, add at Phase C below 40°C at max 0.15%.

## 8. Preservation Rationale

**System:** Phenoxyethanol (0.80%) + Ethylhexylglycerin (0.10%) = 0.90% total.

**Spectrum:** Gram-positive (good), gram-negative (good with EHG boost), yeast (moderate), mould (moderate).

**pH compatibility:** Effective pH 3.0–8.0. Formulation at pH 5.0–5.5 is optimal.

**EU:** Phenoxyethanol max 1.0% (Annex V/29). At 0.80%, compliant with margin.

**India:** Permitted at 1.0% max under Cosmetics Rules 2020.

**Alternatives considered:** SB+KS (pH-dependent, requires <5.5). BIT (higher sensitization, not for facial). Organic acids only (insufficient for aqueous surfactant system).

## 9. Stability Risk Assessment

### 9a. Standard Protocol

Market	ICH Zone	Long-term	Accelerated
EU	II	25°C / 60% RH	40°C / 75% RH
India	IVb	30°C / 75% RH	40°C / 75% RH

#### Identified stability risks:

- Surfactant system clarity — monitor for haze or phase separation at elevated temperature.
- Niacinamide stability — sensitive to prolonged heat. Monitor for nicotinic acid formation (causes flushing) via HPLC.
- pH drift — citric acid buffer capacity is moderate. Monitor pH at all timepoints.
- Xanthan Gum viscosity — may thin slightly at 40°C. Reversible on cooling — check viscosity at 25°C after accelerated storage.
- Preservative efficacy — verify PET (Preservative Efficacy Test) at 3-month accelerated timepoint.

#### Recommended test protocol:

Condition	Timepoints	Tests
25°C / 60% RH	0, 1, 3, 6, 12 mo	Appearance, pH, viscosity, micro
30°C / 75% RH	0, 1, 3, 6, 12 mo	Appearance, pH, viscosity, micro (India long-term)
40°C / 75% RH	0, 1, 3, 6 mo	Appearance, pH, viscosity, micro, centrifuge, PET
4°C	0, 1, 3, 6 mo	Appearance, clarity, phase separation
Freeze-thaw	3 cycles (-10°C/25°C, 24h)	Appearance, viscosity, re-homogeneity

### 9b. Supply Chain Advisory — Tropical Markets



Standard accelerated stability testing at 40°C/75% RH validates shelf-life under controlled storage. However, supply chain infrastructure in India introduces thermal exposure beyond standard protocols. Container and warehouse temperatures routinely exceed 55°C during summer months. Road and rail transport can expose products to sustained temperatures of 50–65°C for 24–72 hours.

Test	Conditions	Duration	Purpose
Elevated thermal stress	55°C	72 hours	Peak warehouse/container exposure
Tropical cycling	25°C → 55°C → 25°C	5 cycles, 12h each	Day/night cycling, non-climate-controlled
Extended accelerated	45°C / 75% RH	3 months	Conservative accelerated for tropical distribution

Pay particular attention to: surfactant system clarity (haze, separation), niacinamide degradation, viscosity changes exceeding  $\pm 15\%$ , and preservative efficacy under thermal stress. This advisory reflects observed distribution conditions — it is not a regulatory requirement.

## 10. Manufacturing Brief

### Equipment requirements:

- Phase A: Jacketed vessel with anchor stirrer, heating to 50°C. Volume: 1.2x batch size.
- Phase B: Small premix vessel for xanthan gum hydration. Low-shear paddle mixer.
- Homogenization: Not required — this is a clear surfactant system, not an emulsion.
- pH measurement: Calibrated pH meter, measure at 25°C (not while warm).
- Filling: Standard liquid filling line. Compatible with tubes, pumps, and squeeze bottles.

### Scale-up considerations:

- Lab (1–5 kg): Follow procedure as written. Manual stirring acceptable.
- Pilot (50–200 kg): Use anchor stirrer at 30–60 RPM for Phase A. Pre-hydrate xanthan in separate vessel with high-shear mixer to prevent lumps at scale. Cool to 40°C using jacket water before Phase C.
- Production (500+ kg): Increase xanthan hydration time to 20 minutes. Consider in-line pH adjustment. Surfactant addition rate should be controlled to prevent foam — add over 15–20 minutes with slow agitation.

### Critical control points:

CCP	Parameter	Specification	Rationale
CCP-1	Temperature at Phase C addition	< 40°C	Preservative and active stability
CCP-2	pH after adjustment	5.0–5.5 at 25°C	Preservative efficacy, viscosity
CCP-3	Final viscosity	2,000–4,000 cP	Product performance, dispensing
CCP-4	Clarity check	Clear, no haze	Surfactant compatibility confirmation

**Estimated batch time:** Lab 45 minutes. Pilot 90 minutes. Production 2–3 hours.

## 11. Technical Ingredient Data

INCI Name	HLB	Solubility	Use Level %	Phase	Key Function
Glycerin	N/A	Water-soluble	2–10	A	Humectant, skin barrier
Niacinamide	N/A	Water-soluble	2–5	A	Brightening, barrier repair
Disodium Laurylglucosides Hydroxypropyl Citrate	N/A	Water-soluble	8–20	A	Mild anionic surfactant
Coco-Glucoside	12	Water-soluble	3–8	A	Nonionic co-surfactant
Cocamidopropyl Betaine	N/A	Water-soluble	3–8	A	Amphoteric, viscosity builder
Xanthan Gum	N/A	Dispersible	0.1–0.5	B	Rheology modifier, pseudoplastic



INCI Name	HLB	Solubility	Use Level %	Phase	Key Function
Centella Asiatica Extract	N/A	Water-soluble	0.5–2	B	Anti-inflammatory, wound healing
Phenoxyethanol	N/A	Slightly soluble	0.5–1.0	C	Broad-spectrum preservative
Ethylhexylglycerin	N/A	Oil-soluble	0.1–0.5	C	Preservative booster, emollient

## 12. Claims Substantiation Protocols

Testing protocols required to substantiate claims in each target market.

Claim	Mkt	Framework	Test Method	Instrument	Study Design	Timeline
Brightening / Skin Tone Evening	EU	EC 655/2013	Chromametry (L*/ITA)	Chromameter CR-400	20–30 subjects, 8 weeks	10–12 weeks
Brightening	India	Cosmetics Rules 2020	Chromametry or dermatologist assessment	Chromameter or clinical grading	20 subjects, 4–8 weeks	6–10 weeks
Gentle / Mild	EU	EC 655/2013	Patch test (HRIPT) or in-use tolerance study	Clinical assessment	50 subjects, single application	6–8 weeks
Gentle / Mild	India	Cosmetics Rules 2020	Dermatologist assessment	Clinical assessment	20 subjects	4–6 weeks

**Note:** Niacinamide at 3% is supported by published clinical data (Hakozaki et al., 2002) demonstrating statistically significant improvement in hyperpigmentation at 8 weeks. This literature evidence strengthens — but does not replace — product-specific claims testing.

## 13. Research Citations

### Niacinamide

Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. *Br J Dermatol.* 2002;147(1):20-31.

PMID: 12100180

Relevance: Demonstrates 4% niacinamide significantly reduces hyperpigmentation at 8 weeks (n=202, double-blind RCT).

Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that improves aging facial skin appearance. *Dermatol Surg.* 2005;31(7 Pt 2):860-865.

PMID: 16029679

Relevance: Topical 5% niacinamide improved fine lines, hyperpigmentation, texture, and red blotchiness vs vehicle.

Wohlrab J, Kreft D. Niacinamide - mechanisms of action and its topical use in dermatology. *Skin Pharmacol Physiol.* 2014;27(6):311-315.

PMID: 24993939

Relevance: Comprehensive review of niacinamide MOA: barrier function, sebum regulation, anti-inflammatory, anti-pigmentary.

### Centella Asiatica

Bylka W, Znajdek-Awizen P, Studzinska-Sroka E, Brzezinska M. Centella asiatica in cosmetology. *Postepy Dermatol Alergol.* 2013;30(1):46-49.

PMID: 24278045

Relevance: Review of centella triterpenoids (asiaticoside, madecassoside) — wound healing, collagen synthesis, anti-inflammatory.

Sun B, Wu L, Wu Y, et al. Therapeutic potential of Centella asiatica and its triterpenes: a review. *Front Pharmacol.* 2020;11:568032.

PMID: 33013406

Relevance: Modern review confirming anti-inflammatory and barrier-repair properties relevant to sensitive-skin formulations.

### Cocamidopropyl Betaine — Sensitization

Schnuch A, Lessmann H, Geier J, Uter W. Contact allergy to cocamidopropyl betaine: IVDK data. *Contact Dermatitis.* 2011;64(4):203-211.

PMID: 21392026

Relevance: Large-scale patch test data. Sensitization attributed primarily to DMAPA and amidoamine impurities, not CAPB itself.



## 14. Regulatory Appendix

Complete per-ingredient, per-market regulatory status with regulation references.

INCI Name	EU (Reg. 1223/2009)	India (IS 4707 / Cosmetics Rules)
Glycerin	Permitted No restrictions	Permitted IS 4707 Part 1
Niacinamide	Permitted No restrictions	Permitted Schedule Q cosmetic ingredient
Disodium Laurylglucosides Hydroxypropyl Citrate	Permitted REACH registered CAS 2481100-10-9	Not listed in IS 4707 Regulatory notification may be required
Coco-Glucoside	Permitted No restrictions	Permitted IS 4707 Part 1
Cocamidopropyl Betaine	Permitted No restrictions	Permitted IS 4707 Part 1
Xanthan Gum	Permitted No restrictions	Permitted IS 4707 Part 1
Centella Asiatica Extract	Permitted No restrictions	Permitted Schedule Q
Phenoxyethanol	Restricted Annex V, Entry 29 Max 1.0% as preservative Formulation: 0.80% ✓	Permitted Max 1.0% Cosmetics Rules 2020 Formulation: 0.80% ✓
Ethylhexylglycerin	Permitted Not classified as preservative	Permitted
Citric Acid	Permitted No restrictions pH adjuster — exempt	Permitted pH adjuster

Confidence indicators are generated using internal evaluation logic across ingredient compatibility, known formulation patterns, regulatory constraints, and category fit. They support expert review — they do not replace laboratory validation or formal safety assessment. All concentrations should be verified against current regulatory limits in target markets before commercial production.

This is a sample report generated to demonstrate platform capabilities.